Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Graft-versus-host disease prophylaxis in unrelated donor transplantation: PTCY vs ATG
2021-000853-17Phase 3Active
- Sponsor
- DKMS
- Start
- Jul 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of cyclophosphamide and antithymocyte globulin rabbit in acute myeloid leukemia (AML), myeloid diseases, myelodysplastic syndrome (MDS) and 2 more (2 arms), sponsored by DKMS. Primary endpoint: Overall survival. Started Jul 2021; status: active.
02
Drugs
cyclophosphamideantithymocyte globulin rabbit
03
Conditions
acute myeloid leukemia (AML)myeloid diseasesmyelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2021-000853-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000853-17.